NCT07106762RecruitingPhase 2
IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment
Bristol-Myers Squibb308 sites in 7 countries470 target enrollmentStarted: September 30, 2025Last updated:
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Bristol-Myers Squibb
- Enrollment
- 470
- Locations
- 308
- Primary Endpoint
- Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507
Study Overview
Brief Summary
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Participants must have histologically confirmed advanced urothelial carcinoma.
- •Participants must be eligible to receive platinum-based chemotherapy.
- •Participants must be Anti-PD-(L)1-experienced (in locally advanced or metastatic setting), either in combination with or sequential to another systemic therapy.
- •Participants treated only in the peri-operative setting must have relapsed within 12 months of the last dose of the treatment.
- •Participants must have ≥ 1 measurable lesion per RECIST v1.
- •Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
Exclusion Criteria
- •Participants must not have platinum-based chemotherapy exposure within 12 months.
- •Participants must not have received >2 prior regimens irrespective of the setting.
- •Participants must not have prior ADC therapy targeting EGFR or HER
- •Participants must not have prior therapy with topoisomerase 1 inhibitor.
- •Participants must not have active, untreated brain metastases.
- •Other protocol-defined inclusion/exclusion criteria apply.
Arms & Interventions
Arm E
Active Comparator
Intervention: Cisplatin (Drug)
Arm E
Active Comparator
Intervention: Gemcitabine (Drug)
Arm E
Active Comparator
Intervention: Carboplatin (Drug)
Arm B
Experimental
Intervention: Iza-bren (Drug)
Arm A
Experimental
Intervention: Iza-bren (Drug)
Arm D
Experimental
Intervention: Iza-bren (Drug)
Arm C
Active Comparator
Intervention: Cisplatin (Drug)
Arm C
Active Comparator
Intervention: Carboplatin (Drug)
Arm C
Active Comparator
Intervention: Gemcitabine (Drug)
Outcomes
Primary Outcomes
Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507
Time Frame: Approximately 3 months
Phase 3: Progression-Free Survival (PFS)
Time Frame: Up to 5 years
Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)
Phase 3: Overall Survival (OS)
Time Frame: Up to 5 years
Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507
Time Frame: Approximately 3 months
Phase 3: Progression-Free Survival (PFS)
Time Frame: Up to 5 years
Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)
Phase 3: Overall Survival (OS)
Time Frame: Up to 5 years
Secondary Outcomes
- Phase 2: Objective Response (OR)(Up to 5 years)
- Phase 2: PFS(Up to 5 years)
- Phase 2: Duration of Response (DOR)(Up to 5 years)
- Phase 2: Time to Response (TTR)(Up to 5 years)
- Phase 2: OS(Up to 5 years)
- Phase 2: Iza-bren antibody-drug conjugate (ADC) concentration(Up to 5 years)
- Phase 2: Iza-bren total antibody concentration(Up to 5 years)
- Phase 2: Iza-bren Ed-04 payload concentration(Up to 5 years)
- Phase 2: Iza-bren observed concentration at end of infusion (Ceoi)(Up to 5 years)
- Phase 2: Iza-bren trough observed concentration (Ctrough)(Up to 5 years)
- Phase 3: OR(Up to 5 years)
- Phase 3: DoR(Up to 5 years)
- Phase 3: TTR(Up to 5 years)
- Phase 3: Time until definitive deterioration in the EORTC QLQ-C30 Global Health Status/Quality of Life (GHS/QoL) scale(Up to 5 years)
- Phase 2: Objective Response (OR)(Up to 5 years)
- Phase 2: PFS(Up to 5 years)
- Phase 2: Duration of Response (DOR)(Up to 5 years)
- Phase 2: Time to Response (TTR)(Up to 5 years)
- Phase 2: OS(Up to 5 years)
- Phase 2: Iza-bren antibody-drug conjugate (ADC) concentration(Up to 5 years)
- Phase 2: Iza-bren total antibody concentration(Up to 5 years)
- Phase 2: Iza-bren Ed-04 payload concentration(Up to 5 years)
- Phase 2: Iza-bren observed concentration at end of infusion (Ceoi)(Up to 5 years)
- Phase 2: Iza-bren trough observed concentration (Ctrough)(Up to 5 years)
- Phase 3: OR(Up to 5 years)
- Phase 3: DoR(Up to 5 years)
- Phase 3: TTR(Up to 5 years)
- Phase 3: Time until definitive deterioration in the EORTC QLQ-C30 Global Health Status/Quality of Life (GHS/QoL) scale(Up to 5 years)
Investigators
Study Sites (308)
Loading locations...
Similar Trials
Completed
Phase 3
AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerAnticancer TreatmentNCT02151981AstraZeneca421
Completed
Phase 2
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone LymphomaMarginal Zone LymphomaB-cell LymphomaNCT01980628Pharmacyclics LLC.63
Completed
Phase 3
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)Waldenström's MacroglobulinemiaNCT03053440BeiGene201
Completed
Phase 2
Phase II Trial GA101 Inbrutinib B CLLLeukemia, Lymphocytic, Chronic, B-CellNCT02666898French Innovative Leukemia Organisation135
Completed
Phase 2
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLLLeukemia, Lymphocytic, ChronicNCT02758665University of Ulm41